Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Mind Medicine (MindMed) Inc MNMD

Alternate Symbol(s):  N.MMED | N.MMED.WA | N.MMED.WR | N.MMED.WS

Healthcare
Mind Medicine (MindMed) Inc. is a clinical-stage biopharmaceutical company, which is engaged in developing products to treat brain health disorders. It is developing a pipeline of product candidates, with and without acute perceptual effects, targeting neurotransmitter pathways. This specifically includes pharmaceutically optimized product candidates derived from the psychedelic and empathogen drug classes, including MM-120 and MM-402, the Company's product candidates. MM120, is a proprietary, pharmaceutically optimized form of lysergide D-tartrate that it is developing for the treatment of generalized anxiety disorder (GAD). MM-120 is also being studied in a subperceptual repeat administration dosing regimen for the treatment of attention deficit hyperactivity disorder (ADHD). MM-402, also referred to as R(-)-MDMA, is the Company's form of the R-enantiomer of 3,4-methylenedioxymethampheta (MDMA), which the Company is developing for the treatment of autism spectrum disorder (ASD).


NDAQ:MNMD - Post by User

Mind Medicine (MindMed) Inc
Bullboard Posts
User Avatar Image
(0)
•••
Post by grumpymonkey007on Nov 12, 2013 5:58pm
463 Views
Post# 21899429

992 All in sustaining costs in Q3

992 All in sustaining costs in Q3

Third Quarter 2013 Financial Highlights

  • Sold 28,344 ounces of gold, a 49% increase over Q3 2012
  • Cash costs of $617 and All in Sustaining Costs (AISC) of $992 per ounce of gold sold
  • Made long-term debt repayments of $4.9 million
  • Revenue of $36.9 million, a 22% increase over Q3 2012
  • Adjusted cash flow from operations of $15.5 million, a 38% increase over Q3 2012

Third Quarter 2013 Operational Highlights

  • Produced 27,174 ounces of gold, a 39% increase over Q3 2012
  • Processed 207,559 tonnes of ore (2,256 tonnes per day) at 4.34 grams per tonne and a 94% recovery
  • Averaged 811 tonnes per day from underground at an average grade of 5.69 grams per tonne
Bullboard Posts
Dealroom for high-potential pre-IPO opportunities